Scott Eggener
University of Chicago
H-index: 78
North America-United States
Top articles of Scott Eggener
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
PRESTO: A phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19) | Journal of Clinical Oncology | Rahul Aggarwal Glenn Heller David W Hillman Han Xiao Joel Picus | 2024/1 |
MP01-12 ACCURACY OF FDG-PET SCAN IN PRIMARY TESTICULAR SEMINOMA: ANALYSIS FROM SEMS TRIAL | Journal of Urology | Brian R Hu Muhannad Alsyouf Clint Cary Timothy Masterson Lawrence Einhorn | 2024/5/1 |
Ex-Vivo Microscopic Onco-Testicular Sperm Extraction: Step-by-Step Surgical Technique at Time of Radical Orchiectomy | Fertility and Sterility | Christopher K Villota Sean W Hou Clark Judge Scott Eggener Gladell Paner | 2024/2/23 |
Stockholm3 validation in a multi-ethnic cohort for prostate cancer (SEPTA) detection: A multicentered, prospective trial. | Hari Thambiah Vigneswaran Martin Eklund Andrea Discacciati Tobias Nordström Rebecca A Hubbard | 2024/2/1 | |
Time to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen | Matthew D Ho Kiang-Teck J Yeo Scott E Eggener | 2024/1/1 | |
Hormonal therapy and radiation therapy in prostate cancer: 5-year outcomes from a trial evaluating combined androgen blockade with 5-alpha reductase inhibitors as an … | Clinical Genitourinary Cancer | Greeshma Rajeev-Kumar Sean P Pitroda Russell Z Szmulewitz Ted Skolarus Scott E Eggener | 2024/4/24 |
Re: Longer is Better for Endoscopic Follow-up of Upper Tract Urothelial Carcinoma After Ureteroscopic Treatment: An Evaluation Spanning 10 Years of Data. | European Urology | Fredrik Liedberg Johannes Bobjer | 2024/1/25 |
Expert perspectives on controversies in castration-sensitive prostate cancer management: narrative review and report of the first US prostate cancer conference part 1 | E David Crawford Alan H Bryce Maha H Hussain Neeraj Agarwal Himisha Beltran | 2024/4/1 | |
MP41-15 GERMLINE DNA DAMAGE REPAIR GENE MUTATIONS IN EARLY STAGE PROSTATE CANCER PATIENTS UNDERGOING ACTIVE SURVEILLANCE OR DEFINITIVE LOCAL TREATMENT | The Journal of Urology | James T Kearns Sarah M Nielsen Emily M Russell Chad Moretz Edward D Esplin | 2024/5 |
Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate Cancer. | European Urology | Andrew J Vickers Melissa Assel Matthew R Cooperberg Samson W Fine Scott Eggener | 2024/1/25 |
Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2 | Alan H Bryce E David Crawford Neeraj Agarwal Maha H Hussain Himisha Beltran | 2024/4/1 | |
PD29-09 PROSTATE CANCER AND SOLID ORGAN TRANSPLANTATION: PATIENT MANAGEMENT AND OUTCOMES | The Journal of Urology | Alon Lazarovich Tanya W Kristof Aaron Dahmen Shavano Steadman Todd Morgan | 2024/5 |
Pivotal study of MRI-guided transurethral ultrasound ablation (TULSA) of localized prostate cancer: 5-year follow up | Christian Pavlovich Scott Eggener Michael Koch David Penson James Relle | 2023 | |
PD50-10 FREE PSA AND RISK OF GLEASON GRADE GROUP≥ 2 AND FATAL PROSTATE CANCER IN BLACK MEN: IMPLICATIONS FOR RISK-STRATIFIED SCREENING | The Journal of Urology | Kendrick Yim Chris Magnani Sigrid Carlsson Martha Shrubsole Kathryn Penney | 2024/5 |
Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study … | Rahul Raj Aggarwal Katherine Dooley David W Hillman Han Xiao Joel Picus | 2023/6/1 | |
Risk stratification of low-risk prostate cancer: individualizing care in the era of active surveillance | Matthew D Ho Ashley E Ross Scott E Eggener | 2023/7/1 | |
Early detection of prostate cancer: AUA/SUO guideline part II: considerations for a prostate biopsy | John T Wei Daniel Barocas Sigrid Carlsson Fergus Coakley Scott Eggener | 2023/7/1 | |
Focal therapy for prostate cancer: evolutionary parallels to breast cancer treatment | Craig V Labbate Laurence Klotz Monica Morrow Matthew Cooperberg Laura Esserman | 2023/1 | |
Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer … | European Journal of Cancer | Luca Antonelli Davide Ardizzone Praful Ravi Aditya Bagrodia Michal Mego | 2023/3/1 |
MP33-01 RISK OF RESIDUAL TERATOMA AFTER COMPLETE RESPONSE FOLLOWING FIRST-LINE CHEMOTHERAPY IN MEN WITH METASTATIC NON-SEMINOMATOUS GERM CELL TUMOR AND IGCCCG INTERMEDIATE/POOR … | The Journal of Urology | Luca Antonelli Davide Ardizzone Praful Ravi Christopher Sweeney Aditya Bagrodia | 2023/4 |
